广生堂：创新药子公司参与乙肝治愈国家科技重大专项

Core Viewpoint - Guangshengtang announced that its subsidiary Guangsheng Zhonglin has been approved to participate in the "Clinical Cure of Chronic Hepatitis B Combined Treatment New Scheme Research" under the National Science and Technology Major Project, which is a recognition of the company's technology and R&D capabilities [1] Group 1 - The project is scheduled to run from December 2025 to November 2028 [1] - Guangsheng Zhonglin is responsible for research work on topics one and three, utilizing innovative hepatitis B drugs GST-HG131, GST-HG141, and combination therapies as research medications [1] - If the project outcomes meet expectations, it will positively impact the development of the company's innovative hepatitis B drugs [1]